Lixte Biotechnology Holdings, Inc., including its subsidiary, Lixte Biotechnology, Inc., is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs compounds to attack those targets. The Company's primary focus is developing new treatments for human cancers. The Company designs drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. This approach has led to the development of over two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. Compounds of both types also have use in the prevention and treatment of neurodegenerative diseases.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:LIXT
- CUSIP: N/A
- Web: www.lixte.com/
- 52 Week Range: $0.09 - $0.42
- Trailing P/E Ratio:
- P/E Growth:
- Return on Assets: -78.67%
Frequently Asked Questions for Lixte Biotechnology Holdings (NASDAQ:LIXT)
What is Lixte Biotechnology Holdings' stock symbol?
Lixte Biotechnology Holdings trades on the NASDAQ under the ticker symbol "LIXT."
How were Lixte Biotechnology Holdings' earnings last quarter?
Who are some of Lixte Biotechnology Holdings' key competitors?
Some companies that are related to Lixte Biotechnology Holdings include Transgenomic (PRPO), Image Sensing Systems (ISNS), Digital Ally (DGLY), Anthera Pharmaceuticals (ANTH), OpGen (OPGN), Novogen Limited (NVGN), Fenix Parts (FENX), Innovus Pharmaceuticals (INNV), Kitov Pharmaceuticals Holdings (KTOV), CounterPath Corporation (CPAH), Galena Biopharma (GALE), Cytori Therapeutics (CYTX), CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (COTQF), Social Reality (SRAX), Celsion Corporation (CLSN), Staffing 360 Solutions (STAF), Lombard Medical (EVAR) and Immune Pharmaceuticals (IMNP).
Who are Lixte Biotechnology Holdings' key executives?
Lixte Biotechnology Holdings' management team includes the folowing people:
- John S Kovach, Chief Executive Officer, Chief Financial Officer, Director
- Stephen J. Forman, Director
- Philip F. Palmedo, Independent Director
How do I buy Lixte Biotechnology Holdings stock?
Shares of Lixte Biotechnology Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lixte Biotechnology Holdings' stock price today?
MarketBeat Community Rating for Lixte Biotechnology Holdings (NASDAQ LIXT)MarketBeat's community ratings are surveys of what our community members think about Lixte Biotechnology Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Lixte Biotechnology Holdings stock can currently be purchased for approximately $0.15.
Consensus Ratings for Lixte Biotechnology Holdings (NASDAQ:LIXT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Lixte Biotechnology Holdings (NASDAQ:LIXT)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Lixte Biotechnology Holdings (NASDAQ:LIXT)Earnings History by Quarter for Lixte Biotechnology Holdings (NASDAQ LIXT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Lixte Biotechnology Holdings (NASDAQ:LIXT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Lixte Biotechnology Holdings (NASDAQ:LIXT)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Latest Headlines for Lixte Biotechnology Holdings (NASDAQ:LIXT)
|Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model|
finance.yahoo.com - April 17 at 10:29 AM
|Late-Breaking Abstract on LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting|
finance.yahoo.com - March 9 at 6:06 PM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - January 16 at 1:18 PM
|First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research|
finance.yahoo.com - January 16 at 1:18 PM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - May 17 at 3:14 PM
|Traumatic Brain Injury Pipeline Market H1 2016 Review Research|
finance.yahoo.com - April 11 at 4:40 PM
|Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players|
www.thestreet.com - April 8 at 7:19 AM
|Sepsis Therapeutics Pipeline Review, H1 2016 - Research and Markets|
finance.yahoo.com - March 23 at 3:46 PM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - February 3 at 4:40 PM
|Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression|
finance.yahoo.com - February 3 at 10:00 AM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale|
biz.yahoo.com - January 26 at 6:02 AM
|Lixte Completes Private Placement of Convertible Preferred Stock|
finance.yahoo.com - January 25 at 10:30 AM
|Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University|
finance.yahoo.com - January 4 at 8:05 PM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statemen|
biz.yahoo.com - December 30 at 3:27 PM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Financials|
finance.yahoo.com - December 8 at 1:17 PM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Financial Statements and Exhibits|
biz.yahoo.com - November 10 at 6:05 AM
|Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity|
finance.yahoo.com - November 6 at 12:30 PM
|Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds|
finance.yahoo.com - September 17 at 1:00 PM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - August 7 at 6:08 PM
|LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 27 at 4:46 PM
Lixte Biotechnology Holdings (LIXT) Chart for Sunday, September, 24, 2017